
The Regional Centre for Biotechnology (RCB), an Institution of National Importance under the auspices of UNESCO, has announced a specialized research opening in Faridabad. This project tackles one of the most significant challenges in modern medicine: the dormancy of Mycobacterium tuberculosis.
Under the guidance of Dr. Prem S. Kaushal, the lab is investigating “ribosome hibernation”—a state where the bacteria’s protein-making factories go into a “sleep mode” to survive antibiotic attacks and the host’s immune system.
Job Details: Project Associate-II
- Number of Positions: 01
- Monthly Fellowship: ₹42,000 + HRA (as applicable)
- Project Title: Exploring ribosome hibernation in Mycobacterium tuberculosis as a potential anti-tuberculosis drug target.
- Deadline: January 23, 2026 (Friday) at 05:00 PM
- Interview Date: January 27, 2026 (Hybrid Mode)
Essential Qualifications
- Education: M.Sc. in Life Sciences with a minimum of 60% marks.
- Exams: Must have cleared NET, DBT-JRF, GATE, or an equivalent national exam.
- Experience: At least two years of R&D experience in industrial or academic institutions.
Desirable Skills
- Hands-on experience in gene cloning and protein purification.
- Familiarity with ribosome purification and Cryo-Electron Microscopy (Cryo-EM) techniques.
- Strong motivation for a long-term career in infectious disease research.
Why This Research Matters
Tuberculosis remains a leading cause of death worldwide. By understanding how the M. tuberculosis ribosome hibernates, researchers can identify “weak spots” in the bacteria’s survival strategy, leading to the development of drugs that can kill even dormant or drug-resistant strains.
Application Checklist
Interested candidates must apply online by the deadline. Ensure you have the following documents ready for upload:
- M.Sc. Mark sheet (Life Science/Biotechnology).
- National Eligibility Certificate (NET/GATE/DBT-JRF).
- Research Publications: Copy of any peer-reviewed manuscripts you have published.
- Age Proof: Candidate must be under 34 years as of Jan 31, 2026.
